[1] Intra J, Salem AK. Fabrication, characterization and in vitro evaluation of poly (D,L-lactide-co-glycolide) micmparticles loaded with polyamidoamine-plasmid DNA dendriplexes for applications in nonviral gene delivery. J Pharm Sci, 2010, 99(1):368-384.
[2] Koning GA, Krijger GC. Targeted multifunetional lipid-based nanocarriers for image-guided drug delivery. Anticancer Agents Med Chem, 2007, 7(4):425-440.
[3] Sawant RR, Torchilin VP. Polymeric micelles:polyethylene glycolphosphatidylethanolamine(PEG-PE)-based micelles as an example. Methods Mol Biol, 2010, 624:131-149.
[4] Press OW, Rasey J. Principles of radioimmunotherapy for hematologists and oncologists. Semin Oncol, 2000, 27(6 Supp112):62-73.
[5] Burke JM, Jurcic JG, Scheinberg DA. Radioimmunotherapy for acute leukemia. Cancer Control, 2002, 9(2):106-113.
[6] Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted (alpha)-particle therapy. J Nucl Med, 2005, 46(Suppl 1):199S-204S.
[7] Lin A, Chen J, Liu Y, et al. Preparation and evaluation of Neaproyl ehitosan nanopartieles surface modified with glyeyrrhizin for hepatoeyte targeting. Drug Dev Ind Pharm, 2009,35(11):13481355.
[8] Li KC, Gueeione S, Bednarski MD. Combined vascular targeted imaging and therapy:a paradigm for personalized treatment. J Cell Biochem Suppl. 2002,39:65-71.
[9] Häfeli UO, Sweeney SM, Beresford BA, et al. Magnetically directed poly (lactic acid) 90Y-micmspheres:novel agents for targeted intracavitary radiotherapy. J Biomed Mater Res, 1994,28(8):901-908.
[10] Chunfu Z, Jinquan C, Duanzhi Y, et al. Preparation and radiolabeling of human serum albumin (HSA)-coated magnetite nanoparticles for magnetically targeted therapy. Appl Radiat Isot, 2004, 61(6):1255-1259.
[11] Kobayashi H, Sato N, Saga T, et al. Monoclonal antibody-dendrimer conjugates enable radiolabeling of antibody with markedly high specific activity with minimal loss of immuno-reactivity. Eur J Nucl Med, 2000, 27(9):1534-1339.
[12] Sato N, Kobayashi H, Saga T, et al. Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice. Clin Cancer Res, 2001, 7(11):3606-3612.
[13] Presant CA, Blayney D, Proffitt RT, et al. Preliminary report:imaging of Kaposi sarcoma and lymphoma in AIDS with indium-111-labelled liposomes. Lancet, 1990,335(8701):1307-1309.
[14] Harrington K J, Rowlinson-Busza G, Syrigos KN, et al. Biodistribution and phatanaeokinetics of Hqn-DTPA-labelled pegylated liposomes in a human tumonr xenograft model:implications for novel targeting strategies. Br J Cancer,2000, 83(2):232-238.
[15] Bao A, Coins B, Klipper R, et al. A novel liposome radiolabelingmethod using 99Tc-"SNS/S" complexes:in vitro and in vivo evaluation. J Pharm Sci,2003,92(9):1893-1904.
[16] Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med, 2002,43(5):693-713.
[17] Chen X, Park R, Shahinian AH, et al. Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol,2004,31(1):11-19.
[18] Line BR,Mitra A,Nan A, et al. Targeting tumor angiogenesis:comparison of peptide and polymer-peptide conjugates. J Nucl Med, 2005, 46(9):1552-1560.
[19] Torchilin VP. Polymeric contrast agents for medical imaging. Curt Pharm Biotechnol, 2000, 1(2):183-215.
[20] Torehilin VP,Lukyanov AN,Gao Z,et al. Immunomicelles:targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci USA, 2003,100(10):6039-6044.